| | MCI-o | Non-AD-D | MCI-AD | AD-D |
|---|
Number of patients | 29 | 14 | 13 | 39 |
Age, yr | 69.4 [61–75] | 65.1 [59–71] | 73.3 [69–77] | 72.5 [68–76]a
|
Sex, M/F | 15/14 | 6/8 | 5/8 | 18/21 |
MMSE | 27 [26–28] | 20 [20–23]b
| 26 [25–28]c
| 21 [19–24]b
|
Aβ1-42, pg/ml | 1262 [1014–1626] | 1255 [997–1585] | 638 [590–852] | 796 [618–928] |
Aβ1-40, pg/ml | 15,393 [12,208–21,112] | 13,332 [9303–22,989] | 21612 [17,875–26,191] | 20,803 [15,168–24,448] |
t-tau, pg/ml | 226 [158–246] | 242 [189–320] | 580 [487–789] | 522 [403–708] |
p-tau, pg/ml | 44 [29–59] | 46 [41–53] | 92 [80–113] | 99 [74–111] |
-
Aβ β-amyloid, p-tau phosphorylated tau, t-tau total tau, MMSE Mini Mental State Examination, MCI-o mild cognitive impairment not due to Alzheimer’s disease, young control subjects without dementia, non-AD-D dementia not due to Alzheimer’s disease, MCI-AD mild cognitive impairment due to Alzheimer’s disease, AD-D Alzheimer’s disease dementia
- The values represent the median [interquartile range]
- Differences between the groups were calculated using a nonparametric Kruskal-Wallis test followed by Dunn’s posttest. No p values were calculated for Aβ, t-tau, and p-tau, as the patients were selected according to these markers
-
a
p < 0.05 vs. non-AD-D
-
b
p < 0.001 vs. MCI-o
-
c
p < 0.01 vs. non-AD-D
